Radiation Oncology

HER2+

Questions discussed in this category

What are your top takeaways in Medical Oncology from SABCS 2025?

6 Answers available

What are your top takeaways from ASCO GI 2026?

6 Answers available

What are your top takeaways in Medical Oncology from SABCS 2024?

13 Answers available

How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?

2 Answers available

How would you manage new symptomatic brain metastases (10-15) in a young woman with HER2+ metastatic breast cancer?

Controlled extracranial disease on trastuzumab+pertuzumab for 2 years. Treatment options include switching systemic rx (T-Dxd, tucatinib) or WBRT. Not...

3 Answers available

What are your top takeaways in Breast Cancer from ESMO 2024?

4 Answers available

How do you approach the treatment of de novo, brain-only metastatic HER2 positive breast cancer?

3 Answers available

What are your top takeaways in Breast Cancer from ASTRO 2024?

4 Answers available

Can trastuzumab deruxtecan be continued during radiation?

The patient has extensive disease, and requires palliative radiation to the scapular area (proximal to the brachial plexus) in a region overlapping wi...

1 Answer available

How would you approach post-operative radiation in a patient with ER/PR negative Her2 positive, T1c N0 breast cancer originating in the ectopic mammary tissue close to the axilla, treated wide excision followed by APT regimen (weekly paclitaxel plus trastuzumab with trastuzumab for one year)?

1 Answer available

What is the rate of a cardiac events that you quote to a patient with preexisting heart disease going on trastuzumab for metastatic Her2+ breast cancer?

How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?

1 Answer available

In which Her2+ breast cancer patients would you recommend extended adjuvant therapy with neratinib?

The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20

Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.

Nat Med, 2022 Aug 08

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Aug 21

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).

Nature medicine, 2024 Sep 13

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Breast cancer research : BCR, 2020 Nov 30

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.

Cureus, 2017 Dec 25

Fractionated Radiosurgery Alone for Thirty-seven Brain Metastases: Not Everything that can be Counted Counts.

The New England journal of medicine, 2024 Sep 15

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Oct 21

A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial.

The New England journal of medicine, 2024 Sep 15

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

BMJ Open, 2019 Oct 15

Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol.

J Clin Oncol, 2020 Jul 30

Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer-Related Lymphedema and Local Tumor Control: Long-Term Results From a Prospective Screening Trial.

JAMA oncology, 2024 Oct 01

Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.

Lancet Oncol., 2019 Jan 30

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 06

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

The New England journal of medicine, 2024 Dec 11

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Lancet Oncol., 2020 Mar 12

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

The New England journal of medicine, 2025 Oct 29

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

JAMA, 2025 Dec 12

Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.

Lancet, 2024 Apr 27

3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 12

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.

Future oncology (London, England), 2023 Aug 01

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

Lancet (London, England), 2023 Oct 20

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.

Future oncology (London, England), 2025 Nov 13

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line V600E-mutant metastatic colorectal cancer.

Related Topics in Radiation Oncology